Adimab Announces First Antibody Technology Transfer and License Agreement with GlaxoSmithKline

  Adimab Announces First Antibody Technology Transfer and License Agreement
  with GlaxoSmithKline

GSK Gains Direct Access to Adimab’s First in Class Antibody Discovery Platform

   Adimab Receives Significant Upfront Payment, Platform Licensing Fees and
             Milestones, and Royalties on Commercialized Products

Business Wire

LEBANON, N.H. -- July 26, 2013

Adimab, LLC, a leader in the discovery of fully human monoclonal and
bispecific antibodies, today announced its first platform technology transfer
and license agreement with GlaxoSmithKline (GSK). Adimab will receive
significant upfront payments, annual licensing fees, and royalties on
resulting commercialized products. Under the agreement, GSK has been granted a
non-exclusive license to use Adimab’s antibody platform for the discovery and
optimization of all antibody formats, including bispecific antibodies.

“Antibody therapeutics offer a tremendous opportunity to address diseases with
serious unmet medical need,” said Tillman Gerngross, Chief Executive Officer
and Co-Founder of Adimab. “Our platform dramatically reduces the preclinical
development timelines and failure rates associated with existing technologies.
This allows companies like GSK to get important protein-based drugs into the
clinic faster. With GSK’s commitment to protein based therapeutics, we expect
them to broadly use the Adimab platform to discover and optimize antibodies,
as well as generate improved bispecific molecules.”

“We surveyed the landscape of comparable technologies and selected what we
believe to be the world-leading antibody discovery and protein engineering
platform to supportour strategy of buildinga strong biopharmaceutical
pipeline at GSK,” said Stephen Martin, Head of Biopharmaceuticals Discovery,
GSK. “GSK is pleased to gain the first full access to this exciting
platform,and the Adimab training and implementation team has shown a strong
commitment to service and support. We had high expectations for the
platformand are very happy with the results to date.Adimabhas been really
collaborative, and we’re looking forward to continuing this productive
relationship.”

Under the terms of the agreement, GSK will have a broad license to the Adimab
antibody discovery platform and a unique custom antibody library that is
exclusive to GSK. In addition, GSK has secured an option to receive continued
access to improvements to the Adimab antibody discovery platform, including
access to subsequently-developed libraries. Adimab will receive a series of
payments, including a significant upfront cash payment, annual license fees
and research and development milestones. Adimab will also receive royalties
and commercial milestones on a defined number of therapeutic products.

“While the Adimab platform has attracted broad interest for more traditional
discovery collaborations, finding the right approach for transferring the
technology to a partner required some creativity. There are a variety of ways
to structure these transactions. We worked closely with GSK to a find a
structure that suited their needs,” said Guy Van Meter, VP of Business
Development at Adimab. “Having a flexible approach will allow us to explore
mutually beneficial structures based on the needs of the partner and the
intended scope of use.”

Over the past four years, Adimab has established partnerships with multiple
leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly,
Genentech, Biogen Idec, Novo Nordisk, Human Genome Sciences, Gilead and Kyowa
Hakko Kirin. Adimab’s partnerships range from single-target funded discovery
projects, to larger multi-target funded discovery collaborations, and now also
include the transfer of the Adimab antibody discovery platform and custom
antibody libraries to pharmaceutical companies. These collaborations focus on
IgG discovery, optimization, humanization and/or bispecifics for therapeutic
products.

About Adimab

Adimab’s integrated antibody discovery and optimization platform provides
unprecedented speed from antigen to purified, full-length human IgGs. Adimab
offers fundamental advantages by delivering diverse panels of therapeutically
relevant antibodies that meet the most aggressive standards for affinity,
epitope coverage, species cross-reactivity and developability. Adimab enables
its partners to rapidly expand their biologics pipelines through a broad
spectrum of technology access arrangements. For more information, visit
http://www.adimab.com.

Contact:

Adimab, LLC.
Guy Van Meter, 603-653-5775
VP of Business Development
 
Press spacebar to pause and continue. Press esc to stop.